Spondyloarthritis & psoriatic arthritis
Treatment-related changes in serum neutrophil gelatinase-associated lipocalin (NGAL) in psoriatic arthritis: results from the PIPA cohort study
Authors' conclusion
Based on these results, serum NGAL does not add any value as a biomarker in patients with peripheral PsA, either for disease activity or for monitoring.
Study context
- Population
- Patients with psoriatic arthritis (PsA) initiating csDMARDs or bDMARDs
- Participants
- 117 / 20 / 20
- Exposure
- PsA patients initiating csDMARD or bDMARD; baseline indirect comparison with psoriasis (PsO) patients and healthy controls
- PsAn = 117
- PsOn = 20
- Healthy controlsn = 20reference
- Outcome
- Changes and trajectories in serum NGAL and clinical outcomes during anti-inflammatory treatment
- Follow-up
- 12 months
Methodological detailsexploratory
- Exploratory
Main finding
As reported in the abstract
Serum NGAL trajectory, all PsA patients · baseline to 12 months
Overall change in NGAL from baseline to 12 months in all PsA patients
−11%
Observational data: associations, not effects.
Further findings
Baseline NGAL, PsA vs control groups
- NGAL in PsA at baseline corresponded to levels in the control groups
Correlation of NGAL changes with PsA outcome changes
- No correlation between changes in NGAL and changes in PsA outcomes
Original publication
Treatment-related changes in serum neutrophil gelatinase-associated lipocalin (NGAL) in psoriatic arthritis: results from the PIPA cohort study. Scand J Rheumatol. Published 20 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →